Related Experiment Video
Updated: Mar 29, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Gene Therapy for Malignant Tumors: Focused on Immunostimulatory Oncolytic Coxsackievirus A11 (CVA11)
Hisanobu Ogata1,2, Haruki Nagano3, Yutaka Fujioka4
1Department of Medical Education, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan; hogata@kyudai.jp.
Abstract:
Gene therapy has emerged as a promising therapeutic strategy in oncology by targeting the molecular mechanisms that drive malignant transformation. Among gene-based approaches, oncolytic viruses (OVs) are distinctive in their ability to selectively replicate within tumor cells, induce direct oncolysis, and simultaneously stimulate systemic antitumor immunity by exploiting defects in cancer cell antiviral responses. Recent studies have identified Coxsackievirus A11 (CVA11) as a highly potent immunostimulatory OV. CVA11 demonstrates strong tumor-selective replication, robust cytolytic activity, and marked induction of antitumor immune responses. Notably, CVA11 has been shown to induce complete tumor regression in human non-small cell lung cancer models. In addition, CVA11 enhances chemosensitivity in oxaliplatin-resistant colorectal cancer and may have broader applicability in treatment-refractory malignancies, including pancreatic cancer. This review summarizes current gene therapy strategies for malignant tumors with a particular focus on the biological properties and therapeutic potential of CVA11. We discuss its mechanisms of tumor selectivity, immune activation, and potential integration with chemotherapy and gene-based cancer vaccines. Collectively, these findings position CVA11 as a promising next-generation oncolytic virus for cancer gene therapy and immunotherapy.
Insights
Coxsackievirus A11 (CVA11) is a potent oncolytic virus that selectively targets cancer cells, inducing tumor regression and stimulating immune responses. This gene therapy approach shows promise for various treatment-refractory malignancies.
Area of Science:
- Oncology
- Virology
- Immunotherapy
Background:
- Gene therapy offers novel strategies for cancer treatment by targeting malignant transformation mechanisms.
- Oncolytic viruses (OVs) selectively replicate in tumor cells, causing oncolysis and stimulating antitumor immunity.
- Cancer cells often have defects in antiviral responses, which OVs exploit for replication.
Purpose of the Study:
- To review current gene therapy strategies in oncology.
- To focus on the biological properties and therapeutic potential of Coxsackievirus A11 (CVA11).
- To discuss CVA11's mechanisms of tumor selectivity, immune activation, and combination potential.
Main Methods:
- Literature review of gene therapy and oncolytic virus research.
- Analysis of studies on Coxsackievirus A11 (CVA11) in cancer models.
- Discussion of CVA11's integration with chemotherapy and cancer vaccines.
Main Results:
- Coxsackievirus A11 (CVA11) exhibits potent immunostimulatory properties as an oncolytic virus.
- CVA11 demonstrates strong tumor-selective replication, cytolytic activity, and robust induction of antitumor immune responses.
- CVA11 achieved complete tumor regression in non-small cell lung cancer models and enhanced chemosensitivity in colorectal cancer.
Conclusions:
- Coxsackievirus A11 (CVA11) is a promising next-generation oncolytic virus for cancer gene therapy and immunotherapy.
- CVA11 shows potential applicability in treatment-refractory cancers, including pancreatic cancer.
- CVA11's ability to activate the immune system makes it a valuable candidate for combination therapies.
More Related Videos
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies